Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference
September 30 2021 - 4:05PM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced that Fred Guerard, PharmD, Chief Executive
Officer of Graybug Vision, will participate in the following events
at the Ophthalmology Innovation Summit (OIS) Retina on Thursday,
October 7, 2021, in San Antonio, Texas. The OIS Retina conference
is being held in conjunction with the American Society of Retina
Specialists (ASRS) 39th Annual Scientific Meeting. Dr. Guerard will
be a speaker at the following events:
- “Innovation Showcase” (company presentation)11:05 a.m. ET /
10:05 a.m. CT / 8:05 a.m. PT; and
- “Finding and Funding Assets in Retina” (panel discussion)4:55
p.m. ET / 3:55 p.m. CT / 1:55 p.m. PT
About GraybugGraybug is a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve. The company’s proprietary ocular delivery technologies are
designed to maintain effective drug levels in ocular tissue for six
months and potentially longer, improving disease management,
reducing healthcare burdens and ultimately delivering better
clinical outcomes. Graybug’s lead product candidate, GB-102, a
formulation of the pan-vascular endothelial growth factor (VEGF)
inhibitor, sunitinib malate targeting a six-month or longer dosing
regimen, inhibits multiple neovascular pathways for the
intravitreal treatment of retinal diseases, including wet
age-related macular degeneration. Graybug’s other product
candidates developed using its proprietary technologies also
include GB-401, an injectable sustained-release formulation of a
beta-adrenergic blocker prodrug, for primary open-angle glaucoma,
with a dosing regimen of once every six months or longer. Founded
in 2011 on the basis of technology licensed from the Johns Hopkins
University School of Medicine, Graybug has offices in Redwood City,
California and in Baltimore, Maryland. For more information, please
visit www.graybug.vision.
Investor ContactIR@graybug.vision(650)
487-2409 |
Media Contactmedia@graybug.vision(404)
384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024